{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to censoring.","groupId":"OG000","lowerLimit":"7.0","upperLimit":"NA","value":"24.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"ISP=all participants who received atleast 1 dose of ixazomib. Overall number of participants analyzed=participants with PN events. As prespecified in SAP,ISP had only 1 arm:Ixazomib (participants originally randomized to ixazomib+participants randomized to placebo prior to Amendment 08 \\&crossed over to ixazomib arm contributing data for this OM from time they initiated ixazomib onward),\\& is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Up to 58.4 months","title":"Time to Resolution of Peripheral Neuropathy (PN) Events","type":"SECONDARY","unitOfMeasure":"days"}